The Role of Complement in Hereditary Angioedema.


Journal

Transfusion medicine reviews
ISSN: 1532-9496
Titre abrégé: Transfus Med Rev
Pays: United States
ID NLM: 8709027

Informations de publication

Date de publication:
10 2019
Historique:
received: 13 07 2019
revised: 15 08 2019
accepted: 16 08 2019
pubmed: 5 11 2019
medline: 20 9 2020
entrez: 3 11 2019
Statut: ppublish

Résumé

Low levels of C1 inhibitor, the main inhibitor of the classic complement system, result in paroxysmal angioedema attacks that can be incapacitating or even life-threatening in affected individuals. Molecular defects in the gene for C1 inhibitor cause hereditary angioedema. In recent years, new insights in the pathways leading to angioedema due to a deficiency of C1 inhibitor have been gathered. Bradykinin, which is formed upon activation of the kallikrein-kinin system under insufficient regulation by C1 inhibitor, plays a crucial role. Whereas C1 inhibitor also occupies a central mediatory role in other plasma systems, such as the contact activation system of coagulation and the fibrinolytic plasminogen-plasmin system, a C1 inhibitor deficiency may also cause enhanced activation of these pathways. Novel therapeutic modalities for treatment and prevention of hereditary angioedema are now available, such as different forms of C1 inhibitor concentrate and novel agents that interfere in the kallikrein-kinin system.

Identifiants

pubmed: 31676220
pii: S0887-7963(19)30104-X
doi: 10.1016/j.tmrv.2019.08.002
pii:
doi:

Substances chimiques

Complement C1 Inhibitor Protein 0
Complement Inactivating Agents 0
SERPING1 protein, human 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-247

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Marcel Levi (M)

University College London Hospitals NHS Foundation Trust, Department of Medicine, UK; Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK; Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands. Electronic address: marcel.levi@nhs.net.

Danny M Cohn (DM)

Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH